Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 341
7
Diseases
44
Unique genes
0.228
Avg. similarity score
Malignant triton tumor
Most-connected disease (6 links)
Disease
Searched: Thyroid gland spindle cell tumor with thymus-like differentiation
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Thyroid gland spindle cell tumor with thymus-like differentiation
Malignant triton tumor
Pleural solitary fibrous tumor
Plexiform neurofibroma
Aneurysmal bone cyst
Pleural sarcomatoid mesothelioma
Spermatogenic failure, x-linked
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Malignant triton tumor | 6 | 6 | 5 |
| Pleural solitary fibrous tumor | 6 | 6 | 6 |
| Plexiform neurofibroma | 6 | 6 | 6 |
| Thyroid gland spindle cell tumor with thymus-like differentiation | 6 | 6 | 5 |
| Aneurysmal bone cyst | 4 | 4 | 9 |
| Pleural sarcomatoid mesothelioma | 4 | 4 | 24 |
| Spermatogenic failure, x-linked | 4 | 4 | 8 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| SSX1 | 7 / 7 | Aneurysmal bone cyst, Malignant triton tumor, Pleural sarcomatoid mesothelioma, Pleural solitary fibrous tumor and 3 more |
| SS18 | 6 / 7 | Aneurysmal bone cyst, Malignant triton tumor, Pleural sarcomatoid mesothelioma, Pleural solitary fibrous tumor and 2 more |
| SSX2 | 6 / 7 | Aneurysmal bone cyst, Malignant triton tumor, Pleural sarcomatoid mesothelioma, Pleural solitary fibrous tumor and 2 more |
| CDKN2A | 2 / 7 | Pleural sarcomatoid mesothelioma, Plexiform neurofibroma |
| KRAS | 2 / 7 | Pleural sarcomatoid mesothelioma, Thyroid gland spindle cell tumor with thymus-like differentiation |
| TP53 | 2 / 7 | Pleural sarcomatoid mesothelioma, Pleural solitary fibrous tumor |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Non-small cell lung cancer | KEGG | 6 / 73 | 22.4× | 2.41e-7 | 1.21e-5 ✓ sig. |
| Bladder cancer | KEGG | 5 / 41 | 33.3× | 3.55e-7 | 1.69e-5 ✓ sig. |
| RAS signaling downstream of NF1 loss-of-function variants | Reactome | 3 / 7 | 117× | 1.59e-6 | 6.23e-5 ✓ sig. |
| EGFR Transactivation by Gastrin | Reactome | 3 / 9 | 91.0× | 3.80e-6 | 1.30e-4 ✓ sig. |
| Melanoma | KEGG | 5 / 73 | 18.7× | 6.52e-6 | 2.04e-4 ✓ sig. |
| Glioma | KEGG | 5 / 76 | 18.0× | 7.96e-6 | 2.41e-4 ✓ sig. |
| GRB2 events in EGFR signaling | Reactome | 3 / 13 | 63.0× | 1.28e-5 | 3.57e-4 ✓ sig. |
| SHC1 events in EGFR signaling | Reactome | 3 / 14 | 58.5× | 1.62e-5 | 4.37e-4 ✓ sig. |
| Constitutive Signaling by EGFRvIII | Reactome | 3 / 15 | 54.6× | 2.02e-5 | 5.27e-4 ✓ sig. |
| Cellular senescence | KEGG | 6 / 157 | 10.4× | 2.12e-5 | 5.47e-4 ✓ sig. |
| Signaling by ERBB2 ECD mutants | Reactome | 3 / 16 | 51.2× | 2.49e-5 | 6.24e-4 ✓ sig. |
| Endocrine resistance | KEGG | 5 / 99 | 13.8× | 2.89e-5 | 7.03e-4 ✓ sig. |
| RAS GTPase cycle mutants | Reactome | 2 / 3 | 182× | 3.93e-5 | 9.01e-4 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 8 / 361 | 6.0× | 4.24e-5 | 9.60e-4 ✓ sig. |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Reactome | 3 / 19 | 43.1× | 4.27e-5 | 9.65e-4 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| negative regulation of cyclin-dependent protein serine/threonine kinase activity | GO:0045736 | 3 / 9 | 142× | 1.01e-6 | 8.68e-5 ✓ sig. |
| Ras protein signal transduction | GO:0007265 | 5 / 79 | 26.9× | 1.13e-6 | 9.52e-5 ✓ sig. |
| MAPK cascade | GO:0000165 | 6 / 147 | 17.3× | 1.18e-6 | 9.84e-5 ✓ sig. |
| glial cell proliferation | GO:0014009 | 3 / 18 | 70.8× | 9.70e-6 | 5.31e-4 ✓ sig. |
| positive regulation of hippo signaling | GO:0035332 | 3 / 21 | 60.7× | 1.57e-5 | 7.72e-4 ✓ sig. |
| Schwann cell proliferation | GO:0014010 | 2 / 3 | 283× | 1.62e-5 | 7.91e-4 ✓ sig. |
| forebrain astrocyte development | GO:0021897 | 2 / 3 | 283× | 1.62e-5 | 7.91e-4 ✓ sig. |
| inner cell mass cell fate commitment | GO:0001827 | 2 / 3 | 283× | 1.62e-5 | 7.91e-4 ✓ sig. |
| inner cell mass cellular morphogenesis | GO:0001828 | 2 / 3 | 283× | 1.62e-5 | 7.91e-4 ✓ sig. |
| negative regulation of cell-matrix adhesion | GO:0001953 | 3 / 22 | 57.9× | 1.82e-5 | 8.61e-4 ✓ sig. |
| regulation of cell cycle | GO:0051726 | 6 / 262 | 9.7× | 3.24e-5 | 1.33e-3 ✓ sig. |
| cell population proliferation | GO:0008283 | 6 / 263 | 9.7× | 3.31e-5 | 1.35e-3 ✓ sig. |
| hippo signaling | GO:0035329 | 3 / 28 | 45.5× | 3.83e-5 | 1.51e-3 ✓ sig. |
| negative regulation of cell population proliferation | GO:0008285 | 7 / 444 | 6.7× | 7.31e-5 | 2.45e-3 ✓ sig. |
| regulation of tissue remodeling | GO:0034103 | 2 / 6 | 142× | 8.08e-5 | 2.64e-3 ✓ sig. |